Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.

ABSTRACT:

Background

Biliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA).

Methods & results

In the current review, we will discuss recent results of clinical trials testing targeted therapies in BRAF-mutant BTCs, with a particular focus on the recently published Phase II ROAR trial and ongoing active and recruiting clinical trials.

Conclusions

Although the extended use of molecular profiling has paved the way toward a new era in BTC management, targeted therapies are limited to iCCA so far, and the prognosis of patients with metastatic disease has substantially

SUBMITTER: Rizzo A 

PROVIDER: S-EPMC8642057 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature